Manufacturer-Prepared Ready-to-Use versus Traditional IV Piggyback Preparation: A Combined Process-Error, Workforce-Time-Waste, and Cost-Effectiveness Analysis
MP-RTU products reduce process errors and operational burdens compared to traditional IV preparations, making them a more effective and cost-efficient option.
Where it sits
this study against the rest of the vasopressin corpusSummary and findings
This study compared the process errors and workforce time associated with manual IV preparation versus manufacturer-prepared ready-to-use (MP-RTU) products. It involved a prospective observation of 100 micafungin and 100 norepinephrine preparations, along with a retrospective analysis of four medications. The findings indicated that MP-RTU products were associated with fewer errors and lower costs.
Abstract
<h4>Background: </h4> Manual IV medication preparation requires multiple discrete steps, each a potential point of process deviation, while manufacturer-prepared ready-to-use (MP-RTU) products avoid many manual compounding steps. Peer-reviewed literature describing and quantifying real-world process-error and workforce-time-waste (WTW) differences between traditional IV piggyback (IVPB) and MP-RTU products remains limited. <h4>Methods:</h4> Two complementary studies were conducted. The Alpha study was a prospective, direct-observation study of 100 micafungin (47 steps) and 100 norepinephrine (15 steps) preparations at a 541-bed hospital. The Bravo study was a retrospective operational analysis of utilization, request burden, time-to-administration, and preparation cost for four medications at a 615-bed hospital. Results informed a decision-analytic cost-effectiveness model (1-year horizon, health-system perspective) comparing MP-RTU with IVPB, with sensitivity analyses. <h4>Results:</h4> Micafungin preparations contained 208 process errors (4.4%; 67% with ≥ 1 error), concentrated in drug withdrawal, syringe assembly, and material collection; norepinephrine preparations contained 100 errors (6.7%; 70% with ≥ 1 error), concentrated in hood preparation/compounding. Pharmacy-prepared insulin and vasopressin showed higher request burden and roughly 2-hour longer time to administration than MP-RTU equivalents. MP-RTU dominated IVPB in the model, with a base-case incremental cost-effectiveness ratio of −$4,954.15 per additional error avoided, robust across sensitivity analyses. <h4>Conclusions:</h4> Manual IV preparation introduced process-error and operational-burden that was either reduced or absent with MP-RTU; this was also less costly and more effective in the model. Findings support considering process-error opportunity and operational burden, not acquisition cost alone, when evaluating IV medication-preparation strategies.
Background
This paper addresses the clinical question of process errors and operational burdens associated with manual IV medication preparation compared to manufacturer-prepared ready-to-use products. Previous literature has indicated that manual preparation involves multiple steps that can lead to errors, but quantification of these differences in a real-world setting has been limited. Understanding these differences is crucial for improving medication safety and efficiency in healthcare settings.
Methods
The study consisted of two complementary analyses. The Alpha study was a prospective, direct-observation study involving 100 micafungin preparations (47 steps) and 100 norepinephrine preparations (15 steps) at a 541-bed hospital. The Bravo study was a retrospective operational analysis at a 615-bed hospital, examining utilization, request burden, time-to-administration, and preparation costs for four medications. A decision-analytic cost-effectiveness model was developed with a 1-year horizon from a health-system perspective.
Results
The primary endpoint indicated that micafungin preparations had 208 process errors (4.4%; 67% with ≥ 1 error), while norepinephrine preparations had 100 errors (6.7%; 70% with ≥ 1 error). The analysis revealed that pharmacy-prepared insulin and vasopressin had a higher request burden and approximately 2-hour longer time to administration compared to MP-RTU products. The cost-effectiveness model showed that MP-RTU had an incremental cost-effectiveness ratio of −$4,954.15 per additional error avoided.
Interpretation
These findings suggest that MP-RTU products may significantly reduce process errors and operational burdens compared to traditional IVPB preparations. While the statistical significance of the findings is clear, the clinical significance regarding the impact on patient outcomes is not directly addressed. Limitations include reliance on observational data and potential confounding factors such as hospital-specific practices and staffing levels.
Key findings
- Micafungin preparations contained 208 process errors (4.4%; 67% with ≥ 1 error).
- Norepinephrine preparations contained 100 errors (6.7%; 70% with ≥ 1 error).
- Pharmacy-prepared insulin and vasopressin showed higher request burden and roughly 2-hour longer time to administration than MP-RTU equivalents.
- MP-RTU dominated IVPB in the model, with a base-case incremental cost-effectiveness ratio of −$4,954.15 per additional error avoided.
Limitations
- Not reported in abstract.
- Observational data may introduce confounding variables.
- Single-site study may limit generalizability.
- Focus on process errors rather than direct patient outcomes.